Immuron Ltd
IMRNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
IMM-124E
Non-alcoholic Steatohepatitis (NASH)
Travelan
Diarrhea
IMM 124-E (Hyperimmune Bovine Colostrum)
Hepatitis, Alcoholic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMM-124E | Phase 2 | Non-alcoholic Steatohepatitis (NASH) | - | - |
Travelan | Phase 2 | Diarrhea | - | - |
IMM 124-E (Hyperimmune Bovine Colostrum) | Phase 2 | Hepatitis, Alcoholic | - | - |
Frequently asked questions
What is in Immuron Ltd's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Immuron Ltd's (IMRN) pipeline across Phase 2. Its lead program is IMM-124E (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immuron Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Immuron Ltd (IMRN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMRN biotech catalysts?→
Add IMRN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immuron Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.